Oral nutritional supplements for gastric cancer – the review of current evidence
The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
A. L. Potapov [verfasserIn] V. E. Khoronenko [verfasserIn] E. V. Gameeva [verfasserIn] Zh. V. Khailova [verfasserIn] A. D. Dorozhkin [verfasserIn] V. Yu. Scoropad [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Issledovaniâ i Praktika v Medicine - QUASAR, LLC, 2016, 8(2021), 1, Seite 53-61 |
|---|---|
| Übergeordnetes Werk: |
volume:8 ; year:2021 ; number:1 ; pages:53-61 |
| Links: |
|---|
| DOI / URN: |
10.17709/2409-2231-2021-8-1-5 |
|---|
| Katalog-ID: |
DOAJ027836347 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ027836347 | ||
| 003 | DE-627 | ||
| 005 | 20230410120137.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17709/2409-2231-2021-8-1-5 |2 doi | |
| 035 | |a (DE-627)DOAJ027836347 | ||
| 035 | |a (DE-599)DOAJaf67b7ca06154ce6b57dfb366a6ee9b3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a A. L. Potapov |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral nutritional supplements for gastric cancer – the review of current evidence |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability. | ||
| 650 | 4 | |a рак желудка | |
| 650 | 4 | |a недостаточность питания | |
| 650 | 4 | |a хирургическое лечение | |
| 650 | 4 | |a гастрэктомия | |
| 650 | 4 | |a субтотальная резекция желудка | |
| 650 | 4 | |a дополнительное пероральное питание | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a V. E. Khoronenko |e verfasserin |4 aut | |
| 700 | 0 | |a E. V. Gameeva |e verfasserin |4 aut | |
| 700 | 0 | |a Zh. V. Khailova |e verfasserin |4 aut | |
| 700 | 0 | |a A. D. Dorozhkin |e verfasserin |4 aut | |
| 700 | 0 | |a V. Yu. Scoropad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Issledovaniâ i Praktika v Medicine |d QUASAR, LLC, 2016 |g 8(2021), 1, Seite 53-61 |w (DE-627)1760599905 |x 24101893 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g number:1 |g pages:53-61 |
| 856 | 4 | 0 | |u https://doi.org/10.17709/2409-2231-2021-8-1-5 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/af67b7ca06154ce6b57dfb366a6ee9b3 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.rpmj.ru/rpmj/article/view/673 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2410-1893 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |e 1 |h 53-61 | ||
| author_variant |
a l p alp v e k vek e v g evg z v k zvk a d d add v y s vys |
|---|---|
| matchkey_str |
article:24101893:2021----::rlurtoasplmnsogsrcacrhrve |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.17709/2409-2231-2021-8-1-5 doi (DE-627)DOAJ027836347 (DE-599)DOAJaf67b7ca06154ce6b57dfb366a6ee9b3 DE-627 ger DE-627 rakwb rus A. L. Potapov verfasserin aut Oral nutritional supplements for gastric cancer – the review of current evidence 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability. рак желудка недостаточность питания хирургическое лечение гастрэктомия субтотальная резекция желудка дополнительное пероральное питание Medicine R V. E. Khoronenko verfasserin aut E. V. Gameeva verfasserin aut Zh. V. Khailova verfasserin aut A. D. Dorozhkin verfasserin aut V. Yu. Scoropad verfasserin aut In Issledovaniâ i Praktika v Medicine QUASAR, LLC, 2016 8(2021), 1, Seite 53-61 (DE-627)1760599905 24101893 nnns volume:8 year:2021 number:1 pages:53-61 https://doi.org/10.17709/2409-2231-2021-8-1-5 kostenfrei https://doaj.org/article/af67b7ca06154ce6b57dfb366a6ee9b3 kostenfrei https://www.rpmj.ru/rpmj/article/view/673 kostenfrei https://doaj.org/toc/2410-1893 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2021 1 53-61 |
| spelling |
10.17709/2409-2231-2021-8-1-5 doi (DE-627)DOAJ027836347 (DE-599)DOAJaf67b7ca06154ce6b57dfb366a6ee9b3 DE-627 ger DE-627 rakwb rus A. L. Potapov verfasserin aut Oral nutritional supplements for gastric cancer – the review of current evidence 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability. рак желудка недостаточность питания хирургическое лечение гастрэктомия субтотальная резекция желудка дополнительное пероральное питание Medicine R V. E. Khoronenko verfasserin aut E. V. Gameeva verfasserin aut Zh. V. Khailova verfasserin aut A. D. Dorozhkin verfasserin aut V. Yu. Scoropad verfasserin aut In Issledovaniâ i Praktika v Medicine QUASAR, LLC, 2016 8(2021), 1, Seite 53-61 (DE-627)1760599905 24101893 nnns volume:8 year:2021 number:1 pages:53-61 https://doi.org/10.17709/2409-2231-2021-8-1-5 kostenfrei https://doaj.org/article/af67b7ca06154ce6b57dfb366a6ee9b3 kostenfrei https://www.rpmj.ru/rpmj/article/view/673 kostenfrei https://doaj.org/toc/2410-1893 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2021 1 53-61 |
| allfields_unstemmed |
10.17709/2409-2231-2021-8-1-5 doi (DE-627)DOAJ027836347 (DE-599)DOAJaf67b7ca06154ce6b57dfb366a6ee9b3 DE-627 ger DE-627 rakwb rus A. L. Potapov verfasserin aut Oral nutritional supplements for gastric cancer – the review of current evidence 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability. рак желудка недостаточность питания хирургическое лечение гастрэктомия субтотальная резекция желудка дополнительное пероральное питание Medicine R V. E. Khoronenko verfasserin aut E. V. Gameeva verfasserin aut Zh. V. Khailova verfasserin aut A. D. Dorozhkin verfasserin aut V. Yu. Scoropad verfasserin aut In Issledovaniâ i Praktika v Medicine QUASAR, LLC, 2016 8(2021), 1, Seite 53-61 (DE-627)1760599905 24101893 nnns volume:8 year:2021 number:1 pages:53-61 https://doi.org/10.17709/2409-2231-2021-8-1-5 kostenfrei https://doaj.org/article/af67b7ca06154ce6b57dfb366a6ee9b3 kostenfrei https://www.rpmj.ru/rpmj/article/view/673 kostenfrei https://doaj.org/toc/2410-1893 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2021 1 53-61 |
| allfieldsGer |
10.17709/2409-2231-2021-8-1-5 doi (DE-627)DOAJ027836347 (DE-599)DOAJaf67b7ca06154ce6b57dfb366a6ee9b3 DE-627 ger DE-627 rakwb rus A. L. Potapov verfasserin aut Oral nutritional supplements for gastric cancer – the review of current evidence 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability. рак желудка недостаточность питания хирургическое лечение гастрэктомия субтотальная резекция желудка дополнительное пероральное питание Medicine R V. E. Khoronenko verfasserin aut E. V. Gameeva verfasserin aut Zh. V. Khailova verfasserin aut A. D. Dorozhkin verfasserin aut V. Yu. Scoropad verfasserin aut In Issledovaniâ i Praktika v Medicine QUASAR, LLC, 2016 8(2021), 1, Seite 53-61 (DE-627)1760599905 24101893 nnns volume:8 year:2021 number:1 pages:53-61 https://doi.org/10.17709/2409-2231-2021-8-1-5 kostenfrei https://doaj.org/article/af67b7ca06154ce6b57dfb366a6ee9b3 kostenfrei https://www.rpmj.ru/rpmj/article/view/673 kostenfrei https://doaj.org/toc/2410-1893 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2021 1 53-61 |
| allfieldsSound |
10.17709/2409-2231-2021-8-1-5 doi (DE-627)DOAJ027836347 (DE-599)DOAJaf67b7ca06154ce6b57dfb366a6ee9b3 DE-627 ger DE-627 rakwb rus A. L. Potapov verfasserin aut Oral nutritional supplements for gastric cancer – the review of current evidence 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability. рак желудка недостаточность питания хирургическое лечение гастрэктомия субтотальная резекция желудка дополнительное пероральное питание Medicine R V. E. Khoronenko verfasserin aut E. V. Gameeva verfasserin aut Zh. V. Khailova verfasserin aut A. D. Dorozhkin verfasserin aut V. Yu. Scoropad verfasserin aut In Issledovaniâ i Praktika v Medicine QUASAR, LLC, 2016 8(2021), 1, Seite 53-61 (DE-627)1760599905 24101893 nnns volume:8 year:2021 number:1 pages:53-61 https://doi.org/10.17709/2409-2231-2021-8-1-5 kostenfrei https://doaj.org/article/af67b7ca06154ce6b57dfb366a6ee9b3 kostenfrei https://www.rpmj.ru/rpmj/article/view/673 kostenfrei https://doaj.org/toc/2410-1893 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2021 1 53-61 |
| language |
Russian |
| source |
In Issledovaniâ i Praktika v Medicine 8(2021), 1, Seite 53-61 volume:8 year:2021 number:1 pages:53-61 |
| sourceStr |
In Issledovaniâ i Praktika v Medicine 8(2021), 1, Seite 53-61 volume:8 year:2021 number:1 pages:53-61 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
рак желудка недостаточность питания хирургическое лечение гастрэктомия субтотальная резекция желудка дополнительное пероральное питание Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Issledovaniâ i Praktika v Medicine |
| authorswithroles_txt_mv |
A. L. Potapov @@aut@@ V. E. Khoronenko @@aut@@ E. V. Gameeva @@aut@@ Zh. V. Khailova @@aut@@ A. D. Dorozhkin @@aut@@ V. Yu. Scoropad @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
1760599905 |
| id |
DOAJ027836347 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027836347</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120137.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17709/2409-2231-2021-8-1-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027836347</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJaf67b7ca06154ce6b57dfb366a6ee9b3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. L. Potapov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oral nutritional supplements for gastric cancer – the review of current evidence</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">рак желудка</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">недостаточность питания</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">хирургическое лечение</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">гастрэктомия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">субтотальная резекция желудка</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">дополнительное пероральное питание</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. E. Khoronenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Gameeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zh. V. Khailova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. D. Dorozhkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. Yu. Scoropad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Issledovaniâ i Praktika v Medicine</subfield><subfield code="d">QUASAR, LLC, 2016</subfield><subfield code="g">8(2021), 1, Seite 53-61</subfield><subfield code="w">(DE-627)1760599905</subfield><subfield code="x">24101893</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:53-61</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17709/2409-2231-2021-8-1-5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/af67b7ca06154ce6b57dfb366a6ee9b3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.rpmj.ru/rpmj/article/view/673</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2410-1893</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">53-61</subfield></datafield></record></collection>
|
| author |
A. L. Potapov |
| spellingShingle |
A. L. Potapov misc рак желудка misc недостаточность питания misc хирургическое лечение misc гастрэктомия misc субтотальная резекция желудка misc дополнительное пероральное питание misc Medicine misc R Oral nutritional supplements for gastric cancer – the review of current evidence |
| authorStr |
A. L. Potapov |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760599905 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
24101893 |
| topic_title |
Oral nutritional supplements for gastric cancer – the review of current evidence рак желудка недостаточность питания хирургическое лечение гастрэктомия субтотальная резекция желудка дополнительное пероральное питание |
| topic |
misc рак желудка misc недостаточность питания misc хирургическое лечение misc гастрэктомия misc субтотальная резекция желудка misc дополнительное пероральное питание misc Medicine misc R |
| topic_unstemmed |
misc рак желудка misc недостаточность питания misc хирургическое лечение misc гастрэктомия misc субтотальная резекция желудка misc дополнительное пероральное питание misc Medicine misc R |
| topic_browse |
misc рак желудка misc недостаточность питания misc хирургическое лечение misc гастрэктомия misc субтотальная резекция желудка misc дополнительное пероральное питание misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Issledovaniâ i Praktika v Medicine |
| hierarchy_parent_id |
1760599905 |
| hierarchy_top_title |
Issledovaniâ i Praktika v Medicine |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760599905 |
| title |
Oral nutritional supplements for gastric cancer – the review of current evidence |
| ctrlnum |
(DE-627)DOAJ027836347 (DE-599)DOAJaf67b7ca06154ce6b57dfb366a6ee9b3 |
| title_full |
Oral nutritional supplements for gastric cancer – the review of current evidence |
| author_sort |
A. L. Potapov |
| journal |
Issledovaniâ i Praktika v Medicine |
| journalStr |
Issledovaniâ i Praktika v Medicine |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
53 |
| author_browse |
A. L. Potapov V. E. Khoronenko E. V. Gameeva Zh. V. Khailova A. D. Dorozhkin V. Yu. Scoropad |
| container_volume |
8 |
| format_se |
Elektronische Aufsätze |
| author-letter |
A. L. Potapov |
| doi_str_mv |
10.17709/2409-2231-2021-8-1-5 |
| author2-role |
verfasserin |
| title_sort |
oral nutritional supplements for gastric cancer – the review of current evidence |
| title_auth |
Oral nutritional supplements for gastric cancer – the review of current evidence |
| abstract |
The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability. |
| abstractGer |
The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability. |
| abstract_unstemmed |
The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
Oral nutritional supplements for gastric cancer – the review of current evidence |
| url |
https://doi.org/10.17709/2409-2231-2021-8-1-5 https://doaj.org/article/af67b7ca06154ce6b57dfb366a6ee9b3 https://www.rpmj.ru/rpmj/article/view/673 https://doaj.org/toc/2410-1893 |
| remote_bool |
true |
| author2 |
V. E. Khoronenko E. V. Gameeva Zh. V. Khailova A. D. Dorozhkin V. Yu. Scoropad |
| author2Str |
V. E. Khoronenko E. V. Gameeva Zh. V. Khailova A. D. Dorozhkin V. Yu. Scoropad |
| ppnlink |
1760599905 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.17709/2409-2231-2021-8-1-5 |
| up_date |
2024-07-03T14:17:14.311Z |
| _version_ |
1803567742912036864 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027836347</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120137.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17709/2409-2231-2021-8-1-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027836347</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJaf67b7ca06154ce6b57dfb366a6ee9b3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. L. Potapov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oral nutritional supplements for gastric cancer – the review of current evidence</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">рак желудка</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">недостаточность питания</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">хирургическое лечение</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">гастрэктомия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">субтотальная резекция желудка</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">дополнительное пероральное питание</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. E. Khoronenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Gameeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zh. V. Khailova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. D. Dorozhkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. Yu. Scoropad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Issledovaniâ i Praktika v Medicine</subfield><subfield code="d">QUASAR, LLC, 2016</subfield><subfield code="g">8(2021), 1, Seite 53-61</subfield><subfield code="w">(DE-627)1760599905</subfield><subfield code="x">24101893</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:53-61</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17709/2409-2231-2021-8-1-5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/af67b7ca06154ce6b57dfb366a6ee9b3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.rpmj.ru/rpmj/article/view/673</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2410-1893</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">53-61</subfield></datafield></record></collection>
|
| score |
7.4026413 |